BioMarin Pharmaceutical Inc. (BMRN) Clinical Hold Appears to be a Conservative Move by the FDA - RBC Capital
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $88.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
